Dr. Shain on Subcutaneous Therapy for Patients With Multiple Myeloma

Kenneth H. Shain, MD, PhD
Published: Tuesday, Aug 08, 2017



Kenneth H. Shain, MD, PhD, assistant member, Moffitt Cancer Center, discusses the impact of subcutaneous therapy, such as bortezomib (Velcade) and daratumumab (Darzalex) for patients with multiple myeloma.

For certain drugs, subcutaneous use of therapy will be important for the field of myeloma, Shain explains. It has changed how physicians take care of patients in helping to mitigate some toxicities, as seen with subcutaneous treatment with bortezomib.

The implementation of this is something that’s going to take time, he says, as it is more of a delivery change versus a mitigation of toxicity change.
SELECTED
LANGUAGE


Kenneth H. Shain, MD, PhD, assistant member, Moffitt Cancer Center, discusses the impact of subcutaneous therapy, such as bortezomib (Velcade) and daratumumab (Darzalex) for patients with multiple myeloma.

For certain drugs, subcutaneous use of therapy will be important for the field of myeloma, Shain explains. It has changed how physicians take care of patients in helping to mitigate some toxicities, as seen with subcutaneous treatment with bortezomib.

The implementation of this is something that’s going to take time, he says, as it is more of a delivery change versus a mitigation of toxicity change.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How to Use Liquid Biopsies Throughout the Lung Cancer Treatment Continuum OnlineJan 31, 20191.5
Community Practice Connections™: Current Status and the Future Potential of CAR T-Cell Therapy for Lymphoid Malignancies: The Experts Weigh-In on Recent Data and Clinical ExperienceJan 31, 20192.0
Publication Bottom Border
Border Publication
x